• Chimeric antigen receptor T-cell therapy (CAR-T) is a targeted, gene-edited cell therapy for
cancer that is approved in Canada for relapsed or refractory high-grade B-cell lymphoma …

Chimeric antigen receptor T-cell (CAR-T) therapy is a revolutionary cancer treatment
modality where a patient's own T cells are collected and engineered ex vivo to express a …

Objectives: To summarize important findings from research on chimeric antigen receptor
(CAR) T-cell immunotherapy in cancer. We discuss CAR design, cell products, toxicity …

Historical standard of care treatments of T-cell malignancies generally entailed the use of
cytotoxic and depleting approaches. These strategies are, however, poorly validated and …

Aggressive B-cell lymphomas that are primary refractory to, or relapse after, frontline
chemoimmunotherapy have a low cure rate with conventional therapies. Although high-dose …

Context.—Chimeric antigen receptor T-cell (CAR-T) technology has shown great promise in
both clinical and preclinical models in mediating potent and specific antitumor activity. With …

Chimeric antigen receptor T-cell (CAR-T) therapy has been prosperous in the treatment of
patients with various types of relapsed/refractory (R/R) B-cell malignancies including diffuse …

Chimeric antigen receptor T (CAR-T) cells represent a novel and personalized therapeutic
approach to cancer immunotherapy. CAR-T cells are genetically engineered, autologous T …

Chimeric antigen receptor T-cell (CAR-T) therapy has become an established therapeutic
approach for the treatment of hematologic malignancies. The field continues to evolve …

The development of immune effector cell (IEC) therapy spans several decades, with early
activity in advanced cancer reported in the late 1980s. 1, 2 Chimeric antigen receptors …